Efficacy of Daptomycin against Bacillus anthracis in a Murine Model of Anthrax Spore Inhalation | Zendy

Henry S. Heine | Zendy; Jennifer Bassett | Zendy; Lynda Miller | Zendy; Bret K. Purcell | Zendy; W. Russell Byrne | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Daptomycin against Bacillus anthracis in a Murine Model of Anthrax Spore Inhalation

Author(s) -

Henry S. Heine,

Jennifer Bassett,

Lynda Miller,

Bret K. Purcell,

W. Russell Byrne

Publication year - 2010

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00210-10

Subject(s) - bacillus anthracis , daptomycin , anthrax vaccines , inhalation , microbiology and biotechnology , spore , bacillus subtilis , bacillus (shape) , biology , medicine , bacteria , immunology , immunization , anesthesia , staphylococcus aureus , vancomycin , antigen , dna vaccination , genetics

Daptomycin demonstrated in vitro (MIC(90), 4 μg/ml) and in vivo activities against Bacillus anthracis. Twice-daily treatment with a dose of 50 mg/kg of body weight was begun 24 h after challenge and continued for 14 or 21 days; results were compared to those for controls treated with phosphate-buffered saline or ciprofloxacin. Day 43 survival rates were 6/10 mice for the 14-day and 9/10 mice for the 21-day treatment groups, compared to survival with ciprofloxacin: 8/10 and 9/10 mice, respectively. Culture results from tissues removed at the termination of the experiment were negative.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research